Faeth Therapeutics, Inc. (FTH)
$20.00-7.02%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $27M
- Beta
- -0.28
- P/E (TTM)
- -0.14
- Short % float
- 838.84%
- Days to cover
- 3.6
- SI change
- +56.8%
- 1W
- -19.74%
- 1M
- -43.45%
- vs SPY 1W
- -18.76%
- vs SPY 1M
- -45.32%
Industry peers
FMP comparable companies · ranked by market cap
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 2$17.95-1.73%
- TNGXSELLTango Therapeutics, Inc.$3.6BRECOVERYQ 23$21.83-0.14%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$4.86-0.85%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 11$17.92-0.29%
- KURASELLKura Oncology, Inc.$947MCRISISQ 12$10.67-2.24%
- VSTMBUYVerastem, Inc.$726MRECOVERYQ 4$8.27+3.49%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on FTH?
- LOPJLB’s latest quantitative signal on Faeth Therapeutics, Inc. (FTH) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is FTH in?
- Faeth Therapeutics, Inc. (FTH) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Faeth Therapeutics, Inc. (FTH) do?
- Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]